XENE Q4 2020 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+54.7% YoY

Gross Profit

-$10M-190.6% margin

Operating Income

-$13M-250.9% margin

Net Income

-$12M-239.3% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-21.4%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$189M

Total Liabilities

$18M

Stockholders' Equity

$171M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+54.7%
Gross Profit	-$10M	$3M	-394.9%
Operating Income	-$13M	-$12M	-11.4%
Net Income	-$12M	-$11M	-8.3%

Revenue Segments

License And Service

$5M100%